Programming immune function through modular assembly of polyionic immune signals

通过聚离子免疫信号的模块化组装来编程免疫功能

基本信息

  • 批准号:
    10533157
  • 负责人:
  • 金额:
    $ 5.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-03-15 至 2023-11-30
  • 项目状态:
    已结题

项目摘要

Vaccination is one of the transformative advances of the last century, allowing prevention of infection with a single dose. However, vaccines for diseases that continue to challenge public health must induce immune responses that are not only potent, but that exhibit tunable features such as polarizing responses toward cell- mediated or antibody-mediated immunity, promoting immunological memory over effector response, or directing immune cells to target tissue. Adjuvants could help deliver this control by activating specific immune pathways, or sets of pathways, that define how antigens are responded to. Toll-like receptor agonists (TLRas), for example, are a growing class of adjuvants that activate stimulatory pathogen-sensing pathways triggered by molecular patterns uncommon in humans, but common in pathogens. Many new studies confirm multifunctional or combination adjuvants able to activate several TLR pathways drive synergistic responses pre-clinically and clinically. However, adjuvant design has historically been dominated by empirical approaches. Thus, new strategies that simplify vaccine composition and create modular platforms for delivery of multiple adjuvants could generate insight into how adjuvants control the nature of immune function, individually or in concert. Biomaterials hold great potential along these lines because these materials offer the ability to deliver multiple cargos. However, many materials – polymer particles, for example – exhibit intrinsic features that can activate inflammatory pathways even in the absence of other immune cues. This feature can be harnessed in vaccination, but also hinders rational design because the role of each vaccine component is clouded by the intrinsic effects of the carrier. Materials that offer features of biomaterials – such as co-delivery – but that improve the modularity and definition of vaccines could provide new knowledge of how combination adjuvants polarize immunity and inform the design of a new generation of vaccines that elicit tunable responses. Toward this goal, we designed a new class of vaccine based on polyelectrolyte multilayers (PEMs) assembled entirely from immune signals. These immune-PEMs (iPEMs) are electrostatically self-assembled from peptide antigens and polyionic TLRas that serve as molecular adjuvants. In this project we will test the hypothesis that juxtaposition of antigens and TLRas in iPEMs can be used to program specific features of antigen-specific immunity. The specific aims are: 1) test if TLRa composition in iPEM correlates to in vitro TLR signaling & polarizes DC/T cell function, 2) test if iPEMs polarize T and B cell function depending on TLRas type and composition in iPEMs, 3) determine how iPEM composition drives local reorganization of LNs & changes in T cell migration, 4) use melanoma as a test bed to assess the efficacy of iPEMs as a function of TLRa combination. Importantly, we will benchmark these materials against potent biomaterial vaccines carriers, and against clinically-relevant adjuvants. Our work will generate new knowledge of how the juxtaposition and combination of antigens and adjuvants promote and polarize immunity, contributing new insight to support more rational vaccine design strategies.
疫苗接种是上个世纪的变革性进步之一,它可以预防甲型h1n1流感的感染

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christopher M Jewell其他文献

Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease
  • DOI:
    10.1182/blood-2024-203585
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Milos D Miljkovic;Adam S. Asch;Gregory Orloff;Ralph Boccia;Jesús G Berdeja;Fevzi Altuntas;Stefan O. Ciurea;James F Howard;Tuan Vu;Bennett Myers;Nizar Chahin;Tahseen Mozaffar;Christopher M Jewell;Metin Kurtoglu
  • 通讯作者:
    Metin Kurtoglu
Enhancing anti-tumor immunity through local gene delivery to lymph nodes
  • DOI:
    10.1186/2051-1426-3-s2-p431
  • 发表时间:
    2015-11-04
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Neil M Dold;Christopher M Jewell
  • 通讯作者:
    Christopher M Jewell
Programming the lymph node microenvironment to enhance anti-tumor T cell immunity in neuroblastoma
  • DOI:
    10.1186/2051-1426-3-s2-p434
  • 发表时间:
    2015-11-04
  • 期刊:
  • 影响因子:
    10.600
  • 作者:
    Joshua M Gammon;Christopher M Jewell
  • 通讯作者:
    Christopher M Jewell

Christopher M Jewell的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christopher M Jewell', 18)}}的其他基金

Defining the induction and maintenance of myelin-specific tolerance in T cells and B cells using local lymph node depots
使用局部淋巴结库定义 T 细胞和 B 细胞中髓磷脂特异性耐受的诱导和维持
  • 批准号:
    10557140
  • 财政年份:
    2022
  • 资助金额:
    $ 5.83万
  • 项目类别:
Defining the induction and maintenance of myelin-specific tolerance in T cells and B cells using local lymph node depots
使用局部淋巴结库定义 T 细胞和 B 细胞中髓磷脂特异性耐受的诱导和维持
  • 批准号:
    10462052
  • 财政年份:
    2022
  • 资助金额:
    $ 5.83万
  • 项目类别:
Programming immune function through modular assembly of polyionic immune signals
通过聚离子免疫信号的模块化组装来编程免疫功能
  • 批准号:
    10401693
  • 财政年份:
    2021
  • 资助金额:
    $ 5.83万
  • 项目类别:
Harnessing biomaterials to study the link between local lymph node function and systemic tolerance
利用生物材料研究局部淋巴结功能与全身耐受性之间的联系
  • 批准号:
    10449748
  • 财政年份:
    2021
  • 资助金额:
    $ 5.83万
  • 项目类别:
Programming immune function through modular assembly of polyionic immune signals
通过聚离子免疫信号的模块化组装来编程免疫功能
  • 批准号:
    10312779
  • 财政年份:
    2019
  • 资助金额:
    $ 5.83万
  • 项目类别:
Programming immune function through modular assembly of polyionic immune signals
通过聚离子免疫信号的模块化组装来编程免疫功能
  • 批准号:
    10064629
  • 财政年份:
    2019
  • 资助金额:
    $ 5.83万
  • 项目类别:
Improving multiple sclerosis patient quality of life using microneedle patches to simplify delivery of MS drugs
使用微针贴片简化多发性硬化症药物的输送,改善多发性硬化症患者的生活质量
  • 批准号:
    10163796
  • 财政年份:
    2019
  • 资助金额:
    $ 5.83万
  • 项目类别:
Programming immune function through modular assembly of polyionic immune signals
通过聚离子免疫信号的模块化组装来编程免疫功能
  • 批准号:
    9889123
  • 财政年份:
    2019
  • 资助金额:
    $ 5.83万
  • 项目类别:
Improving multiple sclerosis patient quality of life using microneedle patches to simplify delivery of MS drugs
使用微针贴片简化多发性硬化症药物的输送,改善多发性硬化症患者的生活质量
  • 批准号:
    10404043
  • 财政年份:
    2019
  • 资助金额:
    $ 5.83万
  • 项目类别:
Harnessing biomaterials to study the link between local lymph node function and systemic tolerance
利用生物材料研究局部淋巴结功能与全身耐受性之间的联系
  • 批准号:
    10066352
  • 财政年份:
    2018
  • 资助金额:
    $ 5.83万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 5.83万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 5.83万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 5.83万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 5.83万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 5.83万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 5.83万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 5.83万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 5.83万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 5.83万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 5.83万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了